End stage liver diseases (ESLD) represent a major, neglected global public health crisis which requires an urgent action towards finding a proper cure. Orthotropic liver transplantation has been the only definitive treatment modality for ESLD. However, shortage of donor organs, timely unavailability, post-surgery related complications and financial burden on the patients limits the number of patients receiving the transplants. Since last two decades cell-based therapies have revolutionized the field of organ/tissue regeneration. However providing an alternative organ source to address the donor liver shortage still poses potential challenges. The developments made in this direction provide useful futuristic approaches, which could be translated into preclinical and clinical settings targeting appropriate app-
INTRODUCTION
End stage liver diseases (ESLD) have become the major reason for the increasing deaths worldwide. According to the World Health Organisation, the total deaths caused by cirrhosis and liver cancer have increased by 50 million/year since 1990 [1] . Liver transplantation is the only standard treatment available so far. However, more than 20% patients die on the waiting list due to a shortage of organ donors [2] . In order to expand the supply of livers available for transplantation, transpl ant surgeons and physicians have explored several new approaches including split liver transplants, living related partial donor procedures [3] and the increasing use of "marginal" organs such as older donors, steato tic livers, nonheartbeating donors, donors with viral hepatitis, and donors with nonmetastatic malignancy [4] . Despite these medical and surgical developments, it is unlikely that the availability of good liver grafts will ever be sufficient to meet the increasing demand of patients with end stage liver disease.
In order to overcome these limitations, various other treatment options are being explored among which hepatocytes transplantation has been described as the first supportive modality in regenerative medicine. But major challenges with such treatment is its limited availability of therapeutic dose from surgical samples, liver grafts or biopsies and their maintenance in vitro which requires celltocell and celltomatrix interac tions for proper functioning of anchorage dependent hepatocytes [5] . Usage of hepatocytes from xenogenic sources such as rabbit, porcine or canine, pose the risk of immunogenicity and transmission of zoonosis. This limitation can be addressed to certain extent by the usage of cell lines which can be maintained for longer time with higher growth rates under in vitro culture conditions but modification of gene expression under culture conditions might lead to problems and has iss ues related to its clinical applicability [6] . The first land mark study to bring hepatocyte tran splantation into clinics was by Mito et al [7] in cirrhotic patients. In line with this study, our centre has treated seven acute liver failure patients by intraperitoneal transplantation of human primary hepatocytes extra cted from human foetus's which showed clinical impro vement and support to the failing liver [8] . Following this, various other studies have reported successful trans plantation of primary hepatocytes in treating various metabolic diseases [9, 10] . Although higher successful rate has been reported using hepatocyte transplantation, yet use of fetal hepatocytes poses major hurdle of ethical issues for its wider clinical applicability. Other potential treatment alternatives discovered in recent years included induced pluripotent stem cells, Mesen chymal stromal cells (MSC) which have the ability to differentiate into hepatocytes but still they couldn't completely mimic the fully functional hepatocytes poin ting towards a need to identify better niche for func tional utilization of these cells [1114] . to isolate enough number of hepatocytes postin vitro expansion which can provide required clinical response in both animal models and human [5, 29] . The in vitro en richment of hepatocytes is challenging due to their contactdependent growth, longterm survival and fun ction and maintenance of normal phenotype without dedifferentiation [5, 30] . Therefore alternative strategies are highly desirable to overcome these limitations.
Recent studies have reported use of embryonic and adult pluripotent stem cells to generate desired number of functional hepatocytes for therapeutic appli cations. However, use of embryonic stem cells (ESCs) represents ethical hurdles and immune incompatibi lity for the transplant recipients [3133] . Moreover, use of induced pluripotent stem cells (iPSCs) has been re ported for effective differentiation into functional hepa tocytes, however poses potential issues related to genetic instability and lack of functional transplantation studies [11, 12] . Mesenchymal stromal cells (MSCs) re presents another alternative type of pluripotent cells to generate functional hepatocytes and support liver regeneration [13, 14] . However, multilineage differentia tion of MSCs represents major challenge to control the effective transdifferentiation into desired number of functional hepatocytes while restricting other default lineage cells. Although, stem cell transplantation stra tegies have showed potential in liver regeneration thr ough various mechanisms, still it has not been consi dered as durable solution to completely support the lost liver functions [15] . Hence, alternative strategies are highly desirable to generate therapeutic number of functional heaptocytes under controlled conditions.
MAJOR SOURCES OF REGENERATIVE CELLS FOR THE TREATMENT OF ESLD

Liver-derived stem sells
These are the stem cells that are derived from adult or fetal livers. Adult stem cells are known as oval cells which play an important role in liver regeneration when replication capacity of hepatocytes is impaired [34] . Fe tal liver stem cells are known as bipotent hepatoblasts that has ability to differentiate into bile duct cells or hepatocytes [3537] . Fetal liver stem cells have been used to repopulate liver in animal models [38, 39] and cultured hepatoblasts transplanted into immunodeficient mice showed greater in vivo engraftment and differentia tion [40] . But the limitation in use of liver derived stem cells is their low number around 0.3% to 0.7% of oval cells in adult liver [41] , whereas fetal liver mass comprises only 0.1% of hepatoblasts [42] and has associated ethical issues. Thus isolation and expansion of these cells and usage for transplantation is challenging.
Bone marrow-derived stem cells
Stem cells derived from bone marrow comprise he matopoietic and MSCs [43] . Among these, mesench ymal stem cells consists greater potential in liver Other alternative of direct cellular transplantation includes the use of extracorporeal liver support devices which can support a failing liver for a short period of time before organ transplantation [15] . But all these above mentioned treatment strategies may not fulfil the requirements to treat ESLD and may not provi de immediate support for a failing liver to maintain normal functions. Hence, there is a need to develop bioengineered transplantable liver grafts which can re tain the natural threedimensional extra cellular matrix (3DECM) components and intact vascular networks similar to the native liver with repopulated functional hepatocytes or human hepatic progenitor cells. Rapid progress in the area of stem cell research and organ bioengineering paved a way in generating alternatives to liver transplantation.
After addressing all these limitations next comes the question of choosing an exact transplantable site where in these bioengineered organs can be easily acceptable and can able to perform the function. Re cently omentum has been discovered as a wonderful ectopic site for transplantation with excellent properties like remarkable angiogenic [16] , stem cell [17, 18] , fibrotic [19] , and immune activities [20] , which together endorse va scularization, promote wound healing, and minimize infection. Several studies have already demonstrated the importance of intraomental transplantation in dia betic animal models [21, 22] . However, the regeneration of liver tissue in ectopic sites is still unknown. Few studies have shown the omentum as a reservoir for proliferat ing renal, pancreatic, splenic [2325] cells and as a site for hepatocytes engraftment which can be used in tissue engineering [26] . Hence, opting omental transplantation of bioengineered liver may offer development of secon dary liver for the treatment of ESLD. This particular approach should offer promising treatment strategy in future and may rule out above mentioned limitations to answer for shortage of organ donors for ESLD.
CURRENT STATE OF REGENERATIVE
STRATEGIES IN ESLD
Since last two decades, significant developments have been made to overcome the limitations of liver transplantation in ESLD. Among these strategies cell transplantation, use of extracorporeal devices and transplantable bioengineered organs have been exp lored extensively.
CELL TRANSPLANTATION
In cell transplantation strategies, hepatocytes tran splantation has been the most preferred cell types for infusion into liver due to their ability to perform major liver specific functions. However, getting therapeutic dose of human hepatocytes represents major limita tion towards its wider clinical application [27, 28] . Although several studies have reported use of 10% liver tissues November 27, 2018|Volume 10|Issue 11| 825 WJH|www.wjgnet.com regeneration [44] with immunosuppressive and immu nomodulatory properties [45] . But they always pose pro blem with low rates of liver repopulation [46] and have low transdifferentiation ability to hepatoblasts which limits to restore normal liver function [47] .
Annex group of stem cells
Stem cells derived from human umbilical cord, human placental tissue, amniotic fluid and human umbilical cord blood constitutes Annex group of stem cells. These are pluripotent stem cells with higher proliferation and differentiation rates than adult stem cells [46, 48, 49] and are not known to cause teratomas or teratocarcino mas formation in humans. Di Campli et al [50] study on diabetic severe combined immunodeficient mice after acute toxic liver injury when treated with intraperito neal administration of human umbilical cord stem cells showed rapid liver engraftment, differentiation into hepatocytes, improved liver regeneration, and reduced mortality rates [50] .
IPSCs
These are similar to ESCs and the limitation of ethical issue can be overruled by in vitro generation of iPSCs from somatic cells avoiding the usage of embryonic tissue or oocytes [51] . However, the use of these cells in clinical practice is limited due to major hurdles with the genomic instability of these cells.
EXTRA-CORPOREAL LIVER SUPPORT
SYSTEMS
Extracorporeal liver support devices have been de signed with a goal to carry out normal liver function in patients with endstage chronic, acuteonchronic and acute liver failure for a short period of time until donor organ gets available. Two types of liver support systems have been designed: (1) Nonbiological; and (2) Bioartificial liver support devices.
Non-biological liver support devices
Designed to filter and adsorb accumulated toxins that are not cleared by nonfunctional liver [52] . Three major types of such devices have been explored as follows:
Molecular adsorbent recirculating system: Mole cular adsorbent recirculating system (MARS) has been well explored device which is a hollow fiber membrane hemodialyzer which removes soluble and proteinbo und substances against albuminrich dialysate. This device was approved by FDA in 2012 for the treatment of hepatic encephalopathy. However, the major limi tation of such devices represents: (1) Shortterm deto xification function; (2) Chance of getting sepsis; (3) Cost issues; (4) Can remove only albuminbound toxins or drugs which are excreted in circulation; (5) Safety and efficacy of MARS has not been demonstrated in controlled, randomized trials; and (6) The effectiveness of MARS in patients that are sedative could not be established in clinical studies and therefore can't be predicted in sedated patients.
Promethus fractionated plasma separator and adsorption system: Other type of devices includes, promethus fractionated plasma separator and ad sorption system (FPSA) which is an artificial device which removes both albuminbound and water soluble toxins from blood more effectively than MARS. However, its wide applicability has been limited due to following reasons: (1) Direct contact between fractionated plasma and the Prometh anion exchanger causes significant adsorption of procoagulant and anticoagulant factors, associated with clinically relevant adverse events; (2) Broad disturbances of the coagulation system have been confirmed in FPSA treated liver failure patients; and (3) An ex vivo recirculation model demonstrated nonspecific adsorption of coagulation factors protein S and protein C on the anion exchange cartridge.
Single-pass albumin dialysis: Moreover, to over come on the limitations of above mentioned extra corporeal liver assist device, singlepass albumin dia lysis (SPAD) system was evolved which functions as onepass dialysis against albumin solution to remove albuminbound toxins and watersoluble substances. Detoxification system in SPAD is similar to or greater than MARS and is less expensive than MARS and FPSA. However, again the suitability and wide clinical app licability of SPAD is limited due to following limitations: (1) Only albumin bound or water soluble toxins can be removed; (2) Lipid soluble toxins can't be removed by SPAD; (3) Bleeding risk from acquired coagulopathy; (4) Albumin solution is discarded after a single passage of membrane without being recycled; and (5) Absence of clinical data.
Bioartificial liver support systems
These are the bioreactors containing viable hepatocytes in a 3D network of hollow fibers. These are designed to achieve plasma perfusion and enhance the activities of living liver cells. Conversely, the membranes separa ting cells from plasma are not capable of achieving enough in vivo perfusion rates, and lack sources of safe, reliable, strongly proliferating and functionally active human cells. Still following major challenges remain to resolve: (1) Bioartificial livers should be able to provide at least 10% of liver functioning; (2) Very difficult acquiring this many hepatocyte cells; (3) Controversy over the use of porcine cells due to po ssible transmission of infections; (4) Hepatocytes and plasma have very different physiochemical properties; (5) Hepatocytes do not perform well when in contact with plasma; (6) Have a very high oxygen uptake rate; (7) Hepatocytes undergo a lot of stress inside of bio artificial liver; (8) Any stress above 5 dyn/cm 2 renders cells useless; (9) Limited volume of the bioreactor;
November 27, 2018|Volume 10|Issue 11| 826 WJH|www.wjgnet.com (10) Maximum blood/plasma that can be safely drawn out of liver failure patient is one liter; (11) Difficult to achieve 10% of liver functioning within one liter; and (12) Makes Bioartificial liver designing very difficult.
TRANSPLANTABLE BIOENGINEERED ORGANS
Owing to the hurdles in above mentioned devices, there is need to develop transplantable biological systems to provide: (1) Suitable threedimensional organ ar chitecture; (2) Organ specific intact vasculature for homogeneous supply of oxygen and nutrients; (3) Longterm cell survival and function within the natural organ specific niche; and (4) Metabolic, synthetic and detoxification functions similar to native liver.
MAJOR COMPONENTS OF HUMAN LIVER FOR BIOENGINEERING
Major components of human liver for bioengineer ing includes (1) Organ specific 3Dbioscaffolds; (2) Organ capsule; (3) Organ vasculature; (4) Cellular distribution in spatial anatomical organization of liver; (5) Biomolecules and growth factors for enhanced su rvival and function to transplanted cells; (6) Types of cells required for longterm support; and (7) Longterm functional response.
To provide these crucial components recently two major technological advancements have been made: (1) Organ bioprinting; and (2) Humanized neoorgan development.
Organ bio-printing
With the advancements in tissue engineering it is possible to construct complex parenchymal organ st ructures along with intact vascular network by 3D bioprinting [53] . 3D bioprinting is one of the prevalent examples of bioengineered organs in the science world today, and it is growing and advancing quickly. This jaw dropping technology is one of the hot topics in bioengineering. It still fascinates that we have the potential to build organs from the push of a button. 3D bioprinting is a form of tissue engineering which utilizes inkjet printers and builds the scaffolding of a particular organ, layer by layer [54] . These inkjet printers allow the use of multiple cell types for printing. Robbins et al [55] developed a metabolically active 3D hepatic tissue where they identified increased liver specific function lasting for up to 135 h, and compartmentspe cific organization, along with a primitive hepatocyte microanatomy of hepatic stellate cells and endothelial cells. Researchers have also build bone repair constru cts by coating the 3D printed scaffold with stem cells, which can grow into tissues over time [54] . The mild con ditions used for bioprinting and material sintering have allowed viable cells and active therapeutic proteins to be incorporated into the construct production process. Today, this particular technology has been emerged only for ex vivo and its application in vivo has not been experienced which needs to be validated further.
Humanized neo-organ development
The recent concept of bioengineering functional hu manized neoorgans has given a hope towards find ing permanent cure as an alternative support to the failing organ. This concept of artificial organs was first originated in the radiation field postWorld War Ⅱ, and was executed in the first bone marrow transplant in the 1970s [56] . According the Llames S tissue engineering has three main constituents: The ex vivo expansion of cells, seeding of these expanded cells in three dimensio nal structures that mimic physiological conditions and grafting the prototype. The technology relies on the development of whole intact organ scaffolds through whole organ perfusion acellularization procedure which retains extracellular matrix and circulatory networks of the native organ postacellularization [57] . This important phenomenon allows threedimensional intact acellular organ specific scaffold for efficient repopulation of desired cell population further to generate functional neoorgan system.
With advancement in regenerative medicine it has been possible to create bioengineered functional tissues or organs that can be used clinically [58, 59] . So far several successful studies have been published in generating various organs and tissues based on these acellularization and stem cell repopulation [5961] that can be used for treating patients. Significant pro gress in generating several types of complex organ biological scaffolds has led to development of an effi cient acellularization protocols for whole organs thr ough perfusion based techniques [6266] (Tables 1 and   2 ). These acellularized whole organs combined with an efficient recellularization process [6770] have made it possible to use these bioengineered organs for in vivo preclinical studies in small animal models [7173] . Our centre has well expertise in generating various types of acellularized whole organ bioscaffolds including xenogeneic liver through detergentbased perfusion. So far, we have successfully generated acellularized and repopulated humanized whole liver and demonstrated its applicability as better natural 3Ddrug testing mo del system [74] . Apart from liver, we have also generated acellularized kidney [75] , heart [76] , spleen, meninges, and many more. Still various other studies are in pipeline in generating humanized bioengineered organs from our centre.
WHOLE LIVER BIOENGINEERING
Highly specialized thick and complex organs like liver can be subjected to acellularization technology to obtain intact 3DECM. Due to delayed comorbidity beyond marginal criteria or because of delayed ischemic time, [77] . This act offers a way to use this kind of livers for acellularization. The liver is the largest gland in the body and carries out numerous essential functions such as metabolism, maintaining homeostasis, and the synthesis of amino acids [57] . Th erefore, acellularization is extremely beneficial to the liver because it not only maintains the microstructure but also its bio signals such as extracellular matrix proteins and adhesion peptides [57] . Since extracellular matrices are similar from spe cies to species, whole organ scaffolds have become possible for livers. Several recent studies have been reported for efficient acellularization of livers obtained from various xenogeneic sources [7881] and the resulting 3DECM structure has become an outstanding sour ce for generating highly functionalized liver cells in vi tro [82, 83] . As these extracellular matrices are conserved between species, the process of recellularization with human cells into an animal scaffold is easier [57] and this kind of approach does not elicit any kind of immune rejection, cross contamination and zoonosis. In our recent study, we have demonstrated development of humanized whole liver using human hepatic progeni tor cells repopulation through hepatic artery infusion into acellularized liver scaffolds [74] . These humanized livers perform detoxification and metabolic functions similar to the native liver. However, the complete re cellularization of a fully function human liver has not yet been accomplished [57] . Recent advances in isolating and culturing both native cells and stem cells, as well as the development of acellularized organ scaffolds and biocompatible synthetic biomaterials, suggest that we are making rapid progress towards providing new alternatives to donor livers for transplantation [56] .
CHALLENGES NEED TO BE ADDRESSED IN GENERATING COMPLETE BIOENGINEERED FUNCTIONAL LIVER
Despite the amazing breakthroughs in the bioengin eered organs, there is much work left to do. Simply reconstructing the whole organ will not be sufficient to replace organ transplantation. The approaches described above are fairly new and are still in the developmental stages. There has been only handful of successful transplantation of bioengineered organs into actual humans. Scientists are still working on ways to engineer more complex organs such as the liver. There are also longterm issues to resolve, such as the preservation of the overall function of these bio engineered organs. However, little is known about the mechanisms by which these grafts may integrate and maintain function. When more complex organs are involved, the scenario is completely different, as investigations are still in very early stages and clinical translation is not foreseeable on the basis of current knowledge and available data [84] . The following major critical issues are yet to be resolved to make these approaches a clinical reality: (1) Liver is a complex organ with various cell types, hence rebuilding liver micro architectures with these cells is yet to be add ressed; (2) The optimal cell source that can meet the criteria for recellularization of acellularized liver sca ffolds still remains unclear; (3) The first and foremost challenge is the need to address the reconstruction of complete and functional uniform endothelial cell layer throughout acellularized liver scaffolds; (4) It is necessary to reconstruct biliary system which is needed for bile acid excretion to develop a fully functional bio engineered liver; (5) Assessing the functionality of these bioengineered livers after in vivo transplanta tion for long term needs to be studied clearly; (6) For organ functionality, maintaining its vascular structure is much more important. As hepatocytes require hi gher amounts of oxygen for their functionality, it is necessary to maintain hierarchical vascular network structure in acellularized liver scaffolds [85] . Critical step in engineering a transplantable liver is the creation of a functional vasculature capable of longterm perfusion following anastomosis. Without an appropriate endo thelial lining of the vessels, continuous blood perfusion of the graft in the absence of anticoagulation quickly results in thrombosis; and (7) Finding an appropriate site for providing enough support to the failing liver has been one of the most challenging issue to use the bioengineered organs as secondary liver.
OMENTUM AS BETTER ECTOPIC SITE FOR TRANSPLANTATION TO GENERATE SECONDARY ORGAN IN VIVO
The major question for applying these humanized bioengineered livers relies on finding an exact and more appropriate transplantable site where in these bioengineered organs can be easily acceptable and are able to perform the function. Recently omentum has been discovered as a potential ectopic site for tra nsplantation with excellent properties like remarkable angiogenic [16] , stem cell [17, 18] , fibrotic [19] , and immune [20] activities, which together endorse vascularization, pr omote wound healing, and minimize infection (Table  3) . Several studies have already demonstrated the im portance of intraomental transplantation in diabetic animal models [22, 86] . The omentum is a visceral adipose tissue derived from mesothelial cells [87] connected to the spleen, stomach, pancreas, and colon [88, 89] . Although well known as a visceral fat depot, the role of the omentum in peritoneal immunity was not recognized until the early 1900s, when a British surgeon referred to it as 'the police man of the abdomen' due to its ability to attenuate peritonitis and promote surgical wound healing [90] . In fact, omentum was noted to move about the peritoneal cavity and occlude sites of inflammation, such as ruptured ovaries, inflamed 829 WJH|www.wjgnet.com appendices, ulcerated intestines, or wounds due to trauma or surgery [90] . Consistent with this observation, the omentum has remarkable angiogenic [16] , fibrotic [19] , regenerative [17, 18] and immune [20] activities, which together promote vascularization, accelerate wound healing, and limit infection. However, these same activities are also likely involved in pathological responses, such as the rapid growth of omental tumour metastases [91] . Once thought of as just a large amount of redun dant fat overlying the intestines, surgeons' attitudes towards the omentum have changed. It is recogni zed as an organ in its own right, with many diverse functions ranging from its ability to attenuate the Process of the callus formation and its mineralisation are much quicker and thicker on the defect that was covered with the free transplant of the greater omentum.
[107]
Pancreatectomized dogs
Spleen or Omentum Islet auto-transplantation Beta cell response to mild non-insulin induced hypoglycemia was normal, whereas the alpha cell response was not.
[108]
Murine carotid artery injury model
Omentum was applied to the injured vessel Omentum + Omental progenitor cells
Omentum can directly contribute reparative progenitor cells to injured tissues upon treatment with Tβ4.
[109]
Nondiabetic nude rats Omentum/kidney capsule Perinatal porcine islet cell grafts
In both sites, the A-cell volume increased fourfold between weeks 1 and 10 reflecting a rise in A-cell number. In the omental implants, however, the cellular insulin reserves and the percent of proliferating cells were twofold higher than in kidney implants. In parallel, the blood vessel density in omental implants increased twofold, reaching a density comparable with islets in adult pig pancreas.
[110]
Diabetic rat and nonhuman primate (NHP) models
Intra-omental
In situ-generated adherent, resorbable plasma thrombin biologic scaffold
Improved metabolic function and preservation of islet cytoarchitecture, with reconstitution of rich intrainsular vascular networks in both species.
[21]
Adult male Spraguee Dawley rats
Omental transposition Hepatic tissue sutured into the omentum mobilization of the omentum and transposition onto the left hepatic lobe
Omental transposition provided adequate microcirculation for proliferation of ectopic hepatic cells after liver resection.
[111]
Vascular bed
Rat omentum showing well established mesenteric circulatory networks which connects all major organs including liver T ra n s p la n ta ti o n o f b io e n g in e e re d h u m a n iz e d li v e r T ra n s p la n te d b io e n g in e e re d h u m a n iz e d li v e r a ft e r The regenerative properties of the omentum have been exploited by surgeons for over a century, ranging from the protection of anastomosis in gastrointesti nal surgery, revascularization of arterial ulcers, to the reconstruction of head and neck deformities [92] . The advantage of the omentum is that it is an accessible and versatile source of growth factors, angiogenic factors, and leukocytes. It can be lengthened con siderably by careful dissection to produce a mobile organ [93] . The regeneration of liver tissue in ectopic sites is still unknown. It has been discovered that the omnetum is a reservoir for proliferating renal, pancreatic, splenic tissues [2325] and as a site for hepatocytes engraftment which can be used in tissue engineering [26] . Hepatocyte transplantation has been done in various tissues like spleen, pancreas and omentum [26, 72, 9496] . With advan cements in tissue engineering hepatocytes seeded onto polymer scaffolds and have been transplanted into omentum wherein engraftment of hepatocytes oc curred due to elevated rates of angiogenesis into cell polymer constructs within the omentum [96] . Thus intraomental transplantation of bioengin eered livers may provide adequate microcirculation for proliferation of ectopic hepatic cells repopulated within the bioartificial liver. It has been observed that portal vein ligation does not affect the ectopic liver regeneration [97] . In our preliminary experiences, we have observed that intraomental transplantation of bioengineered liver lobes gets easily accommodated into the site without eliciting immunological responses while maintain their biological functions and commu nicates blood borne growth factors for survival and function of the graft (Figure 1 ). We also observed that these bioengineered liver grafts survive at omental site in longterm and functions as secondary liver ( Figure  2 ). These findings are well supported by earlier studies wherein other types of grafts have been transplanted into the omentum [21] . Future efforts at understanding mechanisms to regulate ectopic liver regeneration may assist the pursuit for liver tissue/organ bioengineering to support the failing liver functions in longterm.
CONCLUSION
Engineers and researches have been making monu mental breakthroughs in the area of bioengineered organs. These bioartificial organs may redefine tran splants for human applications in future with more critical advancements. The introduction of cells into the human body is designed to stimulate regenera tion, promote vascularization and/or supplement the production of hormones and growth factors [56] . Conse quently, bioengineered biological substitutes present a new way to restore damaged tissue and maintain their functions. Not only does this provide a new source of organs, but probably even more reliable organs at that. Not only would people not need an organ donation, but their body will more readily accept a bioengineered organ through intraomental transplantation, most likely reducing recovery time as well (Figure 3) . In near future these potential strategies can overcome the limitation of organ donors and these bioengineered organs can even serve as a best natural 3Ddrug testing models [74] and investigating precise molecular mechanisms in bio mimetic natural organ system [112] and could support failing liver through ectopic transplantation as secondary organ in ESLD.
